MedTrace Logo

A Study of MK0663/Etoricoxib for Post-Abdominal Hysterectomy Surgery Pain (0663-097)(COMPLETED)

NCT00788710 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 430

Last updated 2022-02-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and safety of etoricoxib compared to placebo in the treatment of postoperative pain associated with total abdominal hysterectomy.

Conditions

  • Acute Pain Following a Total Abdominal Hysterectomy

Interventions

DRUG

etoricoxib (MK0663) 120 mg

120 mg of etoricoxib (MK0663) for a total of 5 days

DRUG

Comparator: Placebo

Placebo tablets once daily on Days 1-5. Total treatment is 5 days.

DRUG

etoricoxib (MK0663) 90 mg

90 mg of etoricoxib (MK0663) for a total of 5 days

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2010-07-31
Completion
2010-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00788710 on ClinicalTrials.gov